High-dose oral vitamin D3 (cholecalciferol) coupled with photodynamic treatment (PDT) can increase squamous precancer clearance (actinic keratoses [AKs]). For a study, researchers sought to determine if oral VD3 can boost the clinical effectiveness of a painless PDT regimen in people with AK.

Serum 25-hydroxyvitamin D3 levels were determined. In group 1, 29 patients underwent gentle debridement and 15-minute aminolevulinic acid preincubation with blue light (30 minutes; 20 J/cm2). In group 2, 29 patients took oral VD3 (10,000 IU daily for 5 or 14 days) prior to debridement and PDT. Lesion clearance was assessed at 3 to 6 months. and baseline lesion numbers were measured. In group 1, 29 patients had mild debridement and a 15-minute preincubation with blue light (30 minutes; 20 J/cm2). Prior to debridement and PDT, 29 patients in Group 2 received oral VD3 (10,000 IU daily for 5 or 14 days). The eradication of the lesion was evaluated after 3 to 6 months. 

In group 1, patients with VD3 insufficiency had lower mean clearance rates of facial AK (25-hydroxyvitamin D3 levels were determined. In group 1, 29 patients underwent gentle debridement and 15-minute aminolevulinic acid preincubation with blue light (30 minutes; 20 J/cm2). In group 2, 29 patients took oral VD3 (10,000 IU daily for 5 or 14 days) prior to debridement and PDT. Lesion clearance was assessed at 3 to 6 months.D3 levels were determined. In group 1, 29 patients underwent gentle debridement and 15-minute aminolevulinic acid preincubation with blue light (30 minutes; 20 J/cm2). In group 2, 29 patients took oral VD3 (10,000 IU daily for 5 or 14 days) prior to debridement and PDT. Lesion clearance was assessed at 3 to 6 months. 31 ng/dL; clearance rate, 40.9± 42%) than patients with normal 25-hydroxyvitamin D3 levels were determined. In group 1, 29 patients underwent gentle debridement and 15-minute aminolevulinic acid preincubation with blue light (30 minutes; 20 J/cm2). In group 2, 29 patients took oral VD3 (10,000 IU daily for 5 or 14 days) prior to debridement and PDT. Lesion clearance was assessed at 3 to 6 months. (62.6%± 14.2%). High-dose VD3 supplementation (group 2) enhanced total AK lesion response (72.5% ±13.6%) when compared to group 1 (54.4%±22.8%). There were no variations in side effects observed. Oral VD3 pretreatment increased AK clinical responses to PDT substantially. The regimen appeared to be effective and well-tolerated.

Reference:www.jaad.org/article/S0190-9622(22)00481-9/fulltext